Biotech + AI Investors

I've reviewed the full data set for July 11-13, 2026, filtered strictly to biotech-AI intersection.

Finding: Zero in-scope signals.

The TOP SIGNALS and RECENT TWEETS contain:

Crypto/macro positioning (@crypto_condom: Bitcoin, $BB, geopolitics)
Sports commentary (@adamfeuerstein, @maverickny: Euro 2024)
Generic portfolio rebalancing (@biotech2k1: $GILD, $REGN, $MSFT, $META, fintech rotation)
One in-scope needle: @adamfeuerstein's AAIC26 preview ($BIIB tau drug, $DNLI BBB penetration) and $AGEN pivot note—but both are 1-2 line mentions with no fresh thesis development beyond prior dispatches

The problem:

Prior three dispatches (Jul 8-10) already crystallized the Wainua collapse, protein developability gating, $BBIO/$ALNY rotation, and $VERA commercial validation
This window's biotech-AI chatter is derivative or off-scope
@biologyaidaily's technical deep-dives (IgGM2, ThermoFusion, FLOWR.ROOT, quantum-priors for MHC peptides) are excellent foundational work but represent published benchmarks, not live market catalysts or conviction repositioning

What would trigger a dispatch: 1. Clinical trial readout or M&A in a biotech-AI play (equivalent to Crinetics $VRTX deal) 2. New regulatory signal (FDA guidance on AI-designed therapeutics) 3. Protein design platform pricing/adoption inflection 4. Conviction shift from tracked sources into/out of $INSM, $BBIO, $PRAX, $VERA, $ALNY

Recommendation: Skip this window. Forced padding would dilute signal quality. Readers expect dispatch only when there's genuine new positioning, dissent, or catalyst. Recycling Jul 8-10 framing weakens credibility.

Resume dispatch when:

AAIC26 (ongoing) produces material biotech-AI intersection calls
Clinical readouts move baseline conviction
Sources actively rotate out of the prior consensus

Biotech + AI Investors — Jul 13